Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F17%3A10362244" target="_blank" >RIV/00216208:11110/17:10362244 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/17:10362244

Výsledek na webu

<a href="http://dx.doi.org/10.1136/heartjnl-2016-309621" target="_blank" >http://dx.doi.org/10.1136/heartjnl-2016-309621</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1136/heartjnl-2016-309621" target="_blank" >10.1136/heartjnl-2016-309621</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension

Popis výsledku v původním jazyce

Objective We compared the haemodynamic effects of riociguat in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent/recurrent CTEPH after pulmonary endarterectomy in the Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate CyclaseStimulator Trial 1 study. Methods Patients with inoperable or persistent/recurrent CTEPH (n= 261; mean +/- SD age 59 +/- 14 years; 66% women) were randomised to riociguat (up to 2.5 mg three times daily) or placebo. Haemodynamic parameters were assessed at baseline and week 16. Results Riociguat decreased pulmonary vascular resistance (PVR) in inoperable (n= 189; least-squares mean difference: -285 dyn s/cm(5) (95% CI -357 to -213); p&lt; 0.0001) and persistent/recurrent (n= 72; -131 dyn s/cm(5) (95% CI -214 to -48); p= 0.0025) patients. Cardiac index improved in inoperable patients by a least-squares mean difference of + 0.6 L/min/m(2) (95% CI 0.4 to 0.7; p&lt; 0.0001), while in persistent/recurrent patients the change was + 0.2 L/min/m(2) (95% CI -0.1 to 0.5; p= 0.17). Mean pulmonary artery pressure decreased in inoperable and persistent/recurrent patients(-4.7 mm Hg (95% CI -6.9 to -2.6; p&lt; 0.0001 and -4.8 mm Hg (-8.2 to -1.5; p= 0.0055), respectively). For all patients, changes in 6 min walk distance correlated with changes in PVR (r=-0.29 (95% CI -0.41 to -0.17); p&lt; 0.0001) and cardiac index (r= 0.23 (95% CI 0.10 to 0.35); p= 0.0004). Conclusions Riociguat improved haemodynamics in patients with inoperable CTEPH or persistent/recurrent CTEPH.

Název v anglickém jazyce

Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension

Popis výsledku anglicky

Objective We compared the haemodynamic effects of riociguat in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent/recurrent CTEPH after pulmonary endarterectomy in the Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate CyclaseStimulator Trial 1 study. Methods Patients with inoperable or persistent/recurrent CTEPH (n= 261; mean +/- SD age 59 +/- 14 years; 66% women) were randomised to riociguat (up to 2.5 mg three times daily) or placebo. Haemodynamic parameters were assessed at baseline and week 16. Results Riociguat decreased pulmonary vascular resistance (PVR) in inoperable (n= 189; least-squares mean difference: -285 dyn s/cm(5) (95% CI -357 to -213); p&lt; 0.0001) and persistent/recurrent (n= 72; -131 dyn s/cm(5) (95% CI -214 to -48); p= 0.0025) patients. Cardiac index improved in inoperable patients by a least-squares mean difference of + 0.6 L/min/m(2) (95% CI 0.4 to 0.7; p&lt; 0.0001), while in persistent/recurrent patients the change was + 0.2 L/min/m(2) (95% CI -0.1 to 0.5; p= 0.17). Mean pulmonary artery pressure decreased in inoperable and persistent/recurrent patients(-4.7 mm Hg (95% CI -6.9 to -2.6; p&lt; 0.0001 and -4.8 mm Hg (-8.2 to -1.5; p= 0.0055), respectively). For all patients, changes in 6 min walk distance correlated with changes in PVR (r=-0.29 (95% CI -0.41 to -0.17); p&lt; 0.0001) and cardiac index (r= 0.23 (95% CI 0.10 to 0.35); p= 0.0004). Conclusions Riociguat improved haemodynamics in patients with inoperable CTEPH or persistent/recurrent CTEPH.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Heart

ISSN

1355-6037

e-ISSN

—

Svazek periodika

103

Číslo periodika v rámci svazku

8

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

8

Strana od-do

599-606

Kód UT WoS článku

000398196000010

EID výsledku v databázi Scopus

2-s2.0-85007553221